Sarah Santos
08/10/2021 sem 0 Comment

Cytiva triples single-use consumables capacity in China

Cytiva continues to expand its single-use consumable bioprocessing manufacturing capabilities in China. In collaboration with Wego Pharmaceutical Co. Ltd, one of the country’s largest healthcare technology providers, the two companies are expanding an existing facility jointly launched in 2018. These newly added manufacturing lines will triple the capacity to supply single-use consumables in the Asia region.

The planned expansion will consist of eight more new manufacturing lines, two of which are scheduled to launch in late 2021; with the other six lines scheduled for the third quarter of 2022. 1,300 square meters will be added to the ISO Class 7 cleanroom manufacturing area and also includes a 1,200 square meter warehouse to further save lead time and increase flexibility for customers.

These expansions are part of the $1.5 billion investment recently announced by Cytiva and Pall Corporation.

In addition to the increased capacity, Cytiva is also bringing new products, Xcellerex mixer bags from 100L to 1,000L, to the expanded facility’s manufacturing portfolio. The new products will incorporate Fortem technology – Cytiva’s materially advanced, single-use characterized film, and their local manufacturing enhances our ability to provide business continuity for our customers.

Francis Van Parys, vice president, Asia Pacific, Cytiva, says: “With increasing global demand, customers demand more flexibility and adaptability, resulting in the growing trend of regional-to-regional manufacturing. Our collaboration with Wego has proven successful for our customers in China, and this increased capability will help the region improve manufacturing resilience with cost efficiencies and reduced lead times, while providing an equivalent high-quality product for our customers in the broader region.”

According to BioPlan’s annual biomanufacturing report, adoption of single-use technology is expected to increase rapidly in clinical production and manufacturing. Over 85% of current pre-commercial and clinical manufacturing lines / facilities are disposable.


Original article: